Human epidermal growth factor receptor 2 (HER2) status is one of the major tumor characteristics
in breast cancer to guide therapy. Anti-HER2 treatment has clear survival advantages …

Accurate determination of tumor human epidermal growth factor receptor 2 (HER2)‐status in
breast cancer patients is possible via noninvasive imaging, provided adequate tracers are …

Camelidae possess an unusual class of antibodies devoid of light chains. Nanobodies are
intact antigen-binding fragments that are stable, easily generated against different targets, …

Nanobodies are the smallest fully functional antigen-binding antibody fragments possessing
ideal properties as probes for molecular imaging. In this study we labeled the anti–human …

Immuno-imaging is a developing technology that aims at studying disease in patients using
imaging techniques such as positron emission tomography in combination with radiolabeled …

Tumor-associated macrophages constitute a major component of the stroma of solid tumors,
encompassing distinct subpopulations with different characteristics and functions. We …

Nanobodies are a novel type of immunoglobulinlike, antigen-binding protein with beneficial
pharmacologic and pharmacokinetic properties that are ideally suited to targeting cellular …

131 I-GMIB-anti-human epidermal growth factor receptor type 2 (HER2)-VHH1 is a targeted
radionuclide theranostic agent directed at HER2-expressing cancers. VHH1 is a single-…

Introduction Radiolabeled nanobodies are exciting new probes for molecular imaging due to
high affinity, high specificity and fast washout from the blood. Here we present the labeling …

Nanobodies show favourable pharmacokinetic characteristics for tumor targeting, including
high tumor‐to‐background‐ratios. Labelled with a therapeutic radionuclide, nanobodies …